Skip to navigation Skip to content



In this article


Many people with MS have concerns about the safety of routine vaccinations and vaccinations required for travel to other countries. The information about each vaccine is based upon the best-available evidence.

General recommendations

The Academy of Neurology, in collaboration with the Immunization Panel of the Multiple Sclerosis Council for Clinical Practice Guidelines, published a summary of evidence and recommendations regarding immunizations and MS. They concluded that:

  • The evidence supports strategies to minimize the risk of acquiring infectious diseases that may trigger MS relapses (also called attacks or exacerbations).

  • The influenza, hepatitis B, varicella and tetanus vaccines are safe for people with MS.

A 2017 systematic review of the published studies of the role of vaccines in the risk of developing MS and or MS relapses found:

  • No change in risk of developing MS after vaccinations against seasonal influenza, hepatitis B, human papillomavirus (HPV), measles-mumps-rubella, variola, tetanus, Bacillus Calmette-Guérin (BCG), polio, or diphtheria;
  • No increased risk of relapse following vaccination against seasonal influenza.

Decisions about the potential benefits and risks of any given immunization should be made in consultation with your healthcare providers, including your family physician and neurologist.

Special considerations

  • People who are experiencing a serious relapse that affects their ability to carry out activities of daily living should defer vaccination until 4-6 weeks after the onset of the relapse.
  • Inactivated vaccines are generally considered safe for people with MS, including those who are taking an interferon medication (Avonex®, Betaseron®, Extavia®, Plegridy®, Rebif®), Aubagio®, Copaxone®, Gilenya®, Glatopa®, Lemtrada®, Novantrone®, Tecfidera® or Tysabri®. 
  • Live and live-attenuated vaccines are generally not recommended for people with MS.
  • People on therapies that suppress the immune system, such as Cytoxan®, Imuran®, Novantrone®, Rheumatrex® and/or chronic corticosteroid therapy, should consult their neurologist before taking any live-virus vaccine. 
  • A person should not receive a live-virus vaccine following a course of Lemtrada®.
  • Any required live and live-attenuated vaccinations should be administered at least 4 weeks before a person starts treatment with Ocrevus®. No live-attenuated or live vaccines should be given during treatment or following treatment until your healthcare providers tells you that your immune system is no longer weakened. When possible a person should receive any non-live vaccines at least 2 weeks before you start treatment with Ocrevus. If you would like to receive any non-live (inactivated) vaccines, including the seasonal flu vaccine, while being treated with Ocrevus, talk to your healthcare provider. If you are pregnant or planning to become pregnant after receiving Ocrevus talk to your healthcare provider about vaccinations for your baby, as some precautions may be needed.
  • You should avoid receiving live vaccines during treatment with Mayzent®. Mayzent® should be stopped 1 week before and for 4 weeks after receiving a live vaccine. If you receive a live vaccine, you may get the infection the vaccine was meant to prevent. Vaccines may not work as well when given during treatment with Mayzent®.
  • You should not receive live or live attenuated vaccines within the 4 to 6 weeks preceding your treatment with Mavenclad®. You should not receive these types of vaccines during your treatment with Mavenclad® and until your healthcare provider tells you that your immune system is no longer weakened.
  • MS experts are not in agreement about the risks for a person with MS whose close family member receives a live-virus vaccine. The family should discuss with the neurologist how best to handle this situation. 

Information about Specific Vaccines

2018-2019  Injectable Seasonal Flu Vaccine 
The composition of U.Sl influenza (flu) vaccines is reviewed annually by the Centers for Disease Control and updated to match circulating flu viruses.

  • The 2018-19 inactivated seasonal flu immunization is recommended by the Centers for Disease Control and Prevention (CDC) for everyone over 6 months of age. The seasonal flu vaccine has been studied extensively in people with MS and is considered quite safe, regardless of the disease-modifying therapy they are taking. People with MS should use the inactivated flu vaccine and avoid the live, attenuated vaccine (nasal spray).
  • A high-dose inactivated flu vaccine (Fluzone High-Dose) is available for people over age 65. The Centers for Disease Control does not specifically recommend the high-dose vaccine for people over age 65 and the high-dose vaccine has not been studied in people with MS of any age. For these reasons, the National MS Society continues to support influenza vaccination (flu shots) for people with MS but recommends that only the standard dose be used. If additional data for Fluzone High-Dose in MS patients become available, the recommendation may be revised.
To learn more about the 2018-2019 seasonal flu vaccine, please visit the CDC website.

Hepatitis B vaccine

  • The hepatitis B vaccine is recommended for all children, adolescents and adults at risk of contracting this potentially life-threatening disease. Note: Reports of an increase in MS cases in France following vaccination for hepatitis B frightened many people into avoiding hepatitis B vaccinations. However, these reports confused a temporal relationship (diagnosis of MS following the vaccine) with a causal relationship (the vaccine caused MS). MS experts are in agreement that the vaccine does not cause MS to occur. Hepatitis B is a serious illness that can safely be prevented with the hepatitis B vaccination.
  • Individuals at risk include anyone working in a job that involves contact with human blood, those who have diabetes and are under age 60, those who have sex with or live in the same house as a person with hepatitis B virus infection, and those who have sex with more than one partner. Additionally, people who live or travel outside the country for more than 6 months a year are also advised to get this vaccine.
  • In 2002, the National Academy of Sciences' Institute of Medicine (IOM) determined that there is no association between hepatitis B vaccination and the onset of MS. A 2017 systematic review of vaccine safety in MS concluded that the hepatitis B vaccine does not increase a person's risk of developing MS.

Human papillomavirus vaccine (Gardasil®).

  • This vaccine is designed to prevent the HPV 6, 11, 16 and/or 18-related cervical cancer, cervical dysplasias, vulvar and vaginal dysplasias, and condyloma acuminate in girls and women ages 9 to 26.
  • One case report (Waldemann et al., 2009) described the onset of acute disseminated encephalomyelitis following the second immunization with Gardasil, and Sutton et al. (2009) reported five patients who presented with multifocal or atypical demyelination syndromes within 21 days of the second or third immunization (three of whom had previously experienced clinical isolated episodes of neurological dysfunction). However, a recent large-scale study of patient registries in Denmark and Sweden (see below) found no increased risk of developing MS among nearly 800,000 who received this vaccine. Use of Gardasil should be preceded by a discussion between patient and physician regarding benefits and risks.
Pneumococcal vaccines (Pneumovax® 23 - PPSV23) and Prevnar® 13-PCV13)
  • PCV13 protects against 13 types of penumococcal bacteria; PPSV23 protects against 23 types of pneumococcal bacteria.
  • One dose of PDV13 is recommended for all adults 65 years or older who have not previously received the vaccine. A dose of PPSV23 should be given at least one year later.
  • For adults 65 and older who have already received one or more doses of PPSV23, the dose of PCV13 should be given at least one year after receiving the most recent dose of PPSV23.
  • Both pneumococcal vaccines are inactivated and safe for people with MS.
  • According to the American Academy of Neurology recommendations on immunizations for people with MS, pneumococcal vaccine should be considered for individuals with compromised pulmonary function, including those who use a wheelchair on a full-time basis or are bed-bound.
Shingles vaccine (Shingrix®)
  • The CDC recommends Shingrix, a non-live vaccine for the prevention of herpes zoster (shingles) and related complications. The vaccine, which is given in two doses separated by 2 to 6 months, is recommended over Zostavax® (the previously approved vaccine for shingles). Shingrix is approved for adults 50 years and older:
    • whether or not they have had a prior episode of herpes zoster or have had a dose of Zostavax
    • who have a chronic medical condition, unless there is a specific reason why the individual should not have it
    • who are getting other adult vaccines such as influenza and pneumococcal (pneumonia) vaccines
  • No studies of Shingrix have been done in people with MS. However, in two clinical studies with Shingrix, there was no increase in immune-mediated conditions.
  • The CDC indicates that a person who is taking a low-dose immunosuppressive therapy or is going to begin taking an immunosuppressive medication can take Shingrix. It is very important to discuss this vaccine with the healthcare provider who is treating your MS to ensure that it is appropriate for you.
 Smallpox vaccine
  • While this vaccine has not been studied in people with MS, it should be made available to any person with MS directly exposed to smallpox as the risks associated with not getting vaccinated would be too great.

Varicella vaccine

  • This vaccine should be considered by people with MS who have never had chicken pox, lack evidence of prior immunity, and are considering starting an MS medication that has the potential to suppress cell mediated immunity – for example, Gilenya® (fingolimod) and Lemtrada™ (alemtuzumab).
  • The vaccine should be taken six weeks before starting the MS therapy.

Studies of Vaccine Safety and Effectiveness in People with MS

Some, but not all, immunizations have been evaluated for safety and efficacy in people with MS:

  • A study by the Vaccines in Multiple Sclerosis Study Group published in 2001 in the New England Journal of Medicine found that vaccination for tetanus, hepatitis B or influenza  did not appear to increase the short-term risk of relapses (also called attacks or exacerbations) in people with MS.
  • A study by the National Immunization Program of the Centers for Disease Control and Prevention, published in the Archives of Neurology in 2003, found that vaccination against hepatitis B, influenza, tetanus, measles, or rubella did not increase a person’s risk of developing MS or optic neuritis (which is often a first symptom of MS). 
  • A small, unblinded study, published in the Archives of Neurology in 2011, of people with relapsing-remitting MS who received the yellow fever vaccination prior to travel, found a significantly increased risk of MS relapses during the six weeks following the  vaccination when compared to the remainder of the two-year follow-up period. For people with MS who must travel to areas where yellow fever is common, the increased relapse risk needs to be carefully weighed against the likelihood of exposure to yellow fever – which is a potentially fatal illness.
  • A study of nearly four million girls and women identified in nationwide patient registries in Denmark and Sweden, published in the Journal of the American Medical Association, found no increased risk of developing MS among nearly 800,000 who received quadrivalent human papillomavirus vaccine (Gardasil®), designed to prevent cervical cancer. 
  • A review of data from the complete electronic medical health records of Kaiser Permanente Southern California between 2008 and 20011, published in JAMA Neurology, found no long-term association of vaccines with MS or any other acquired central nervous system demyelinating disease.

Studies of Vaccines with Specific Disease Modifying Therapies

  • A blinded, randomized, multicenter, placebo-controlled study, published in Neurology in 2015, evaluated the effectiveness of the flu vaccine in fingolimod-treated patients. Researchers found that most fingolimod-treated patients with MS were able to mount immune responses with the vaccine, and the majority met criteria indicating seroprotection. However, response rates were reduced compared with placebo-treated patients.  Overall, there was some decrease in vaccination-induced immune responses among the fingolimod treated patients. 
  • A study, published in Neurology in 2013, investigated the effect of teriflunomide on the efficacy and safety of the influenza vaccine and found that teriflunomide-treated patients generally mounted effective immune responses to seasonal influenza vaccination. Researchers concluded that teriflunomide generally does not adversely impact the ability of MS patients to mount immune responses to influenza vaccination. 
  • A small case-control study, published in Neurology in 2013, assessed immunocompetence in patients after alemtuzumab treatment by measuring antibody responses to several vaccines before and after treatment.  Researchers concluded that serum antibodies against common viruses remained detectable after treatment, and there was retained ability to mount an immune response against new antigens after treatment with alemtuzumab. 
  • In a small study published in Neurology, Neuroimmunology and Neuroinflammation in 2016, comparing people being treated with daclizumab with a group comprised of healthy controls and people with MS not being treated with daclizumab, no difference was found in the two groups’ ability to mount a normal antibody response to influenza vaccinations.

Summary Table of Vaccine Recommendations

Summary Table of Vaccine Recommendations
Vaccine Type Use in people with MS
Injectable seasonal flu vaccine Inactivated Considered safe
Flu-Mist® flu vaccine Live attenuated Not recommended
Fluzone® high-dose flu vaccine Inactivated Not recommended
Gardisil® human papillomavirus vaccine (HPV) Inactivated Probably safe
Hepatitis B vaccine Inactivated Considered safe
Measles-Mumps-Rubella vaccine Live attenuated Probably safe in individuals not on immunosuppressant medications
Pneumovax® 23 and Prevnar® 13 pneumococcal vaccines Inactivated Considered safe
Polio Inactivated in most countries Probably safe
Rabies Inactivated Probably safe; benefit likely outweighs any risks
Tetanus vaccine Inactivated Considered safe; may reduce relapses
Varivax® and Proquad® varicella vaccines Live attenuated Probably safe. Required prior to treatment with fingolimod and alemtuzumab in patients without previous exposure
Yellow fever vaccine Live attenuated May not be safe; should not be used by individuals on immunosuppressant medications
Zostavax® zoster vaccine Live attenuated Probably safe for any adult who has had chicken pox
Adapted from  Williamson EML, Chahin S, Berger JR. Vaccines in multiple sclerosis. Curr Neurol Neurosci Rep 2016; 16:36. DOI 10.1007/s11910-016-0637-6